RFAs: Accelerating the Development of Combined CGM–Pump Devices

The focus areas include benchtop, in vitro, and preclinical development and validation of combined CGM–pump devices, including studies evaluating device integration, compatibility of sensing and insulin delivery components, and overall system performance, as well as feasibility studies and clinical evaluation of combined CGM–pump devices, including assessments of safety, usability, wearability, and clinical utility.

A combined CGM–pump device integrates two essential diabetes management technologies into a single device, offering a potential approach to reduce the burden associated with wearing and managing multiple devices for people with type 1 diabetes.

The development of these integrated devices involves technical and commercialization challenges, including the need for improvements in device compatibility and lifespan, system reliability, scalable manufacturing, affordability, and broad accessibility.

The opportunity also recognizes that a potential insulin dilution effect may require adjustments to CGM algorithms. Research projects supported through this funding opportunity are expected to address key technical, clinical, and translational challenges related to combined CGM–pump devices.

Letters of Intent are invited from academic and industry applicants with innovative approaches to developing combined CGM–pump devices. Applications may request up to $900,000 USD for projects lasting up to three years, with funding levels determined by the scope and objectives of the proposed work.

Breakthrough T1D may consider proposals with increased scope, time, or budget when strongly justified. Smaller budget projects will also be considered, and requested funding should align with the proposed studies and available resources required for successful completion.

Eligible applicants include domestic and foreign non-profit organizations, public and private institutions such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible federal agencies. Applicants must hold an M.D., D.O., D.M.D., D.V.M., Ph.D., or equivalent qualification and have a faculty position or equivalent role at a research facility or academic institution.

Applications from for-profit entities or industry collaborations with academia may also be submitted, with additional information requested from for-profit entities if a full application is invited. Breakthrough T1D welcomes proposals from qualified individuals and encourages participation from a broad cross section of researchers and scientists.

For more information, visit Breakthrough T1D.